Interventional Oncology Market

The global interventional oncology market is set for strong growth, projected to expand from US$2.1 billion in 2024 to US$3.5 billion by 2031, registering a CAGR of 8.1% during the forecast period. This momentum reflects the increasing adoption of minimally invasive cancer treatments, rising global cancer prevalence, and technological innovations in ablation and imaging techniques.

Interventional oncology—a subspecialty of interventional radiology—focuses on using image-guided, minimally invasive procedures to diagnose and treat cancer. It has emerged as a key alternative to traditional surgical approaches, offering reduced recovery times, lower risks, and improved patient outcomes.

Key Highlights of the Market

• Minimally invasive techniques such as radiofrequency ablation (RFA) are boosting adoption worldwide.

• Cryoablation and microwave ablation offer benefits over conventional surgery, fueling market demand.

• Enhanced sedation, pain management, and patient monitoring techniques improve treatment safety and patient comfort.

• Ablation devices are expected to expand substantially, with an 8.7% CAGR projected through 2031.

• North America continues to lead the market, while Asia Pacific is expected to record the fastest growth.

• Advanced imaging technologies like high-resolution MRI and CT scans are creating new opportunities.

Market Overview

Market Size and Growth Projections

• 2024 Market Size: US$2.1 Bn

• 2031 Market Size: US$3.5 Bn

• Global CAGR (2024–2031): 8.1%

• Historical CAGR (2019–2023): 7.3%

The market’s trajectory demonstrates consistent growth, supported by increasing cancer incidence and growing demand for effective, minimally invasive therapies.

Regional Insights

North America: Market Leader with 8.3% CAGR

North America remains the dominant region, projected to grow at a CAGR of 8.3% through 2031. Factors driving this growth include:

• Advanced healthcare infrastructure and specialized cancer centers.

• Strong focus on medical innovation and R&D investments.

• High prevalence of cancer, particularly lung and liver cancers.

• Availability of skilled professionals and favorable reimbursement frameworks.

The region has also witnessed accelerated adoption of advanced ablation technologies and embolization techniques, supported by robust regulatory approvals.

Asia Pacific: Fastest Growing Market

The Asia Pacific region is expected to post the fastest growth rate, driven by:

• Rapidly rising cancer incidence in densely populated nations.

• Expanding healthcare infrastructure in countries like China and India.

• Government initiatives focused on cancer care expansion.

• Growing awareness and acceptance of minimally invasive oncology procedures.

Notably, India has recently adopted cryoablation and microwave ablation technologies at leading hospitals, signaling rapid acceptance of innovative therapies.

Market Segmentation

By Product Type: Ablation Devices Lead with 8.7% CAGR

Among product types—ablation devices, radiation therapy devices, and embolization devices—ablation devices dominate. Their projected CAGR of 8.7% through 2031 reflects their growing use in treating tumors across organs like the liver, kidneys, and lungs.

Radiofrequency ablation, cryoablation, and microwave ablation techniques have revolutionized tumor management by providing targeted, precise, and minimally invasive treatment.

By Cancer Type: Lung Cancer Takes the Lead

• Lung cancer is projected to grow at 8.7% CAGR, making it the leading cancer type in this market.

• Rising global incidence of lung cancer, coupled with demand for minimally invasive and targeted therapies, drives adoption of interventional techniques.

• Interventional oncology procedures like embolization and ablation are increasingly preferred over surgery, especially for inoperable tumors.

Other significant segments include liver cancer and kidney cancer, both witnessing rising demand for minimally invasive treatments.

By End User: Hospitals Remain Primary Centers

Hospitals continue to dominate the market due to:

• Availability of advanced imaging systems.

• Skilled interventional radiologists.

• Integration of oncology departments with research facilities.

However, ambulatory surgical centers are gaining ground due to lower costs and faster recovery times.

Market Trends and Innovations

1. Shift Toward Personalized Medicine

Interventional oncology is aligning with the personalized medicine trend, with treatments increasingly tailored to individual tumor biology and patient needs.

2. Technological Innovations

• Advanced imaging tools (high-resolution MRI, CT, and PET scans) allow precise tumor localization.

• Next-gen ablation tools enhance accuracy and minimize damage to surrounding healthy tissues.

• AI-based imaging and navigation systems are being developed to assist radiologists in treatment planning.

3. Improved Patient Experience

Innovations in sedation, pain management, and patient monitoring are reducing discomfort and enhancing safety, making interventional oncology more patient-centric.

Growth Drivers

Rising Cancer Incidence

The growing global cancer burden is the single most important driver. According to WHO, global cancer cases are projected to exceed 29 million annually by 2040, underscoring the urgent need for effective treatments.

Preference for Minimally Invasive Therapies

Patients and providers increasingly prefer minimally invasive solutions, as they:

• Reduce hospital stays.

• Lower surgical risks.

• Enable faster recovery.

Advancements in Imaging and Device Technology

Modern imaging enables real-time monitoring, while device innovation enhances precision and safety, making interventional oncology an attractive alternative to surgery.

Restraints

Limited Accessibility in Emerging Markets

Despite strong growth prospects, accessibility remains a challenge in low and middle-income countries:

• Lack of specialized cancer care centers.

• Limited availability of advanced imaging systems.

• High cost of interventional oncology procedures.

These disparities highlight the need for improved healthcare infrastructure and global initiatives to bridge the treatment gap.

Opportunities

Development of Next-Generation Devices

Opportunities lie in creating more precise ablation tools, advanced catheters, and integrated theranostic devices that combine diagnostics and treatment.

Expansion in Emerging Markets

Rapid healthcare modernization in Asia, Latin America, and the Middle East presents significant expansion opportunities for global players.

Competitive Landscape

The market is moderately consolidated, with global players expanding portfolios through R&D, acquisitions, and partnerships.

Key Players Include:

• Medtronic Plc.

• Boston Scientific Corporation

• Profound Medical

• AngioDynamics

• Terumo Corporation

• Siemens Healthineers

• Hologic, Inc.

• Teleflex Incorporated

Recent Developments

• Jan 2024: Delcath Systems, Inc. announced the first commercial use of HEPZATO KIT for metastatic uveal melanoma, delivering higher drug exposure to the liver while limiting systemic toxicity.

• May 2023: IceCure Medical installed its ProSense Cryoablation System at Kovai Medical Center, India, expanding access to minimally invasive tumor-freezing technology.

Outlook

The interventional oncology market has grown steadily at a 7.3% CAGR between 2019 and 2023, and is expected to accelerate further with an 8.1% CAGR through 2031.

The combination of rising cancer incidence, patient preference for less invasive care, and ongoing technological innovations ensures a positive long-term outlook. As healthcare systems shift towards cost-effective and personalized oncology solutions, interventional oncology is poised to play a transformative role in global cancer treatment.

Read Related Reports:

Std Self Diagnostics Market

Hepatoprotective Supplement Market

Rapid Adenovirus Testing Market

Automated Insulin Delivery Market